{"id":26727,"date":"2021-12-16T12:03:25","date_gmt":"2021-12-16T11:03:25","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=26727"},"modified":"2022-03-02T14:21:59","modified_gmt":"2022-03-02T13:21:59","slug":"45-me-per-al-desenvolupament-de-tecnologies-denginyeria-genetica-dultima-generacio","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/45-me-per-al-desenvolupament-de-tecnologies-denginyeria-genetica-dultima-generacio\/","title":{"rendered":"4,5 M\u20ac per al desenvolupament de tecnologies d&#8217;enginyeria gen\u00e8tica d&#8217;\u00faltima generaci\u00f3"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">L&#8217;empresa spin-off del <a rel=\"noreferrer noopener\" href=\"https:\/\/www.upf.edu\/web\/biomed\" target=\"_blank\">Departament de Ci\u00e8ncies Experimentals i de la Salut, Universitat Pompeu Fabra (DCEXS-UPF)<\/a> <a rel=\"noreferrer noopener\" href=\"https:\/\/integra-tx.com\/\" target=\"_blank\"><strong>Integra Therapeutics<\/strong><\/a> ha rebut recentment <a href=\"https:\/\/www.upf.edu\/web\/biomed\/inici\/-\/asset_publisher\/Us0jfwFAevmx\/content\/id\/253376461\/maximized\" target=\"_blank\" rel=\"noreferrer noopener\">4,5 milions d&#8217;euros<\/a> procedents de diferents inversors per a <strong>desenvolupar el projecte durant els pr\u00f2xims dos anys<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;empresa, sorgida des del <a rel=\"noreferrer noopener\" href=\"https:\/\/www.upf.edu\/web\/synbio\" target=\"_blank\">Grup de Recerca en Biologia Sint\u00e8tica Translacional<\/a> del DCEXS-UPF, est\u00e0 fundada pel <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/marc-guell-hem-dexplotar-millor-el-talent-i-excellencia-que-te-barcelona-a-nivell-de-transferencia-de-coneixement\/\" target=\"_blank\"><strong>Marc G\u00fcell<\/strong><\/a>, l\u00edder del grup, i <strong>Avencia S\u00e1nchez-Mej\u00edas<\/strong>, investigadora postdoctoral. El seu objectiu \u00e9s \u201cabordar les limitacions actuals de l&#8217;edici\u00f3 gen\u00e8tica\u201d a trav\u00e9s del desenvolupament d&#8217;una plataforma d&#8217;escriptura de gens amb <strong>aplicacions cl\u00edniques.<\/strong><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201cGr\u00e0cies al suport dels inversors podrem seguir desenvolupant aquesta tecnologia amb un alt potencial per curar malalties que avui no tenen tractament\u201d<br><strong>Avencia S\u00e1nchez-Mej\u00edas<\/strong> (DCEXS-UPF) fundadora i CEO d&#8217;Integra Therapeutics<\/p><\/blockquote>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Es tracta de la tecnologia <strong>Find Cut-and-Transfer (FiCAT)<\/strong>, que combina <a rel=\"noreferrer noopener\" href=\"https:\/\/ellipse.prbb.org\/ca\/edicio-del-genoma-amb-crispr\/\" target=\"_blank\">CRISPR <\/a>i la transposasa piggy Bac (PB), que permet inserir fragments grans d&#8217;ADN en el genoma de manera precisa i segura. Aix\u00ed, des de l&#8217;empresa es busca desenvolupar <a href=\"https:\/\/ellipse.prbb.org\/ca\/un-acord-estrategic-per-accelerar-el-desenvolupament-de-nous-farmacs\/\" target=\"_blank\" rel=\"noreferrer noopener\">ter\u00e0pies avan\u00e7ades<\/a> destinades a la <strong>prevenci\u00f3 i tractament de malalties gen\u00e8tiques i alguns tipus de c\u00e0ncer.<\/strong><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La spin-off de la UPF Integra Therapeutics ha rebut fons de diferents inversors per a acabar el seu prototip tecnol\u00f2gic i impulsar el projecte durant els pr\u00f2xims dos anys.<\/p>\n","protected":false},"author":9,"featured_media":26689,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[28,26],"tags":[307,312,564,708,332,638,726,273,589,757],"new-type":[35],"class_list":["post-26727","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunitat","category-recerca","tag-biologia-sintetica","tag-cancer-ca","tag-edicio-genomica","tag-genetica","tag-gens","tag-industria","tag-innovacio","tag-melis-upf-ca","tag-tecnologia","tag-tractament","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/26727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=26727"}],"version-history":[{"count":2,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/26727\/revisions"}],"predecessor-version":[{"id":26733,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/26727\/revisions\/26733"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/26689"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=26727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=26727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=26727"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=26727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}